MindMed to Participate in H.C. Wainwright Global Investment Conference USA – English USA – English USA – English Post published:September 7, 2022 Post category:Press Release
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch Post published:September 7, 2022 Post category:Press Release
PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022 Post published:September 7, 2022 Post category:Press Release
Wesana Announces Sale of Clinic Management Services Organization Post published:September 3, 2022 Post category:Press Release
Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough Post published:September 2, 2022 Post category:Press Release
COMPASS Pathways to participate in three upcoming investor events Post published:September 1, 2022 Post category:Press Release
Optimi Health Provides Progress Report On Year Of Commercialization Post published:September 1, 2022 Post category:Press Release
FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL Post published:September 1, 2022 Post category:Press Release
Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders Post published:September 1, 2022 Post category:Press Release
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome Post published:August 31, 2022 Post category:Press Release